vivia
BIOTECH

Overview

The **FDA Modernization Act 2.0** is changing the scope of research allowing the use of other alternative methods to the use of animals in your non-clinical drug development, such as ex vivo cell-based assays, to investigate the safety and efficacy of your drugs

Click to learn more

Click for custom assays in solid tumors

Click for custom assays in hematological malignancies

Santiago Grisolia 2
28760 . Madrid . Spain
(+34) 91 129 3151
admin@viviabiotech.com
www.viviabiotech.com



FDA 2.0: Advancing Preclinical Development with Real Patient Samples and Cell-Based Assays

Vivia Biotech have access to real patient samples derived from individuals with hematological malignancies, providing a more clinically relevant and ethically sound methodology for evaluating drug efficacy and safety in contrast to traditional animal models. This approach can expedite drug development and enhance the overall success rate of new therapies in these challenging diseases.



Cost Efficiency

Ethical Considerations
3R's principles

Regulatory Compliance

Clinical Relevance

Adaptability & Flexibility

Disease Heterogeneity

Human Biology

Risk Mitigation at Early Stages



Predictive Value

Faster Results

Rapid Screening

MoA Insights

Drug Resistance

Drug Efficacy

Drug Safety

Personalized Medicine

Disease Progression & Evolution

Early Identification of Promising Compounds

Vivia 2D & 3D ex vivo assays using Native Environment hematological patient samples provide numerous advantages compared to conventional cell lines, isolated primary cells or even animal models

vivia
BIOTECH

Overview

The FDA Modernization Act 2.0 is changing the scope of research allowing the use of other alternative methods to the use of animals in your non-clinical drug development, such as ex vivo cell-based assays, to investigate the safety and efficacy of your drugs

Click to learn more

Click for custom assays in solid tumors

Click for custom assays in hematological malignancies

Santiago Grisolia 2
28760 . Madrid . Spain
(+34) 91 129 3151
admin@viviabiotech.com
www.viviabiotech.com

Vivia Biotech ex vivo assays

- Proprietary functional Native Environment assays with whole peripheral blood (PB) and bone marrow (BM) patient samples
- Our ex vivo assays have attained translational pharmacology that exhibits a remarkable 92% clinical predictability for identifying sensitive AML patients, demonstrating an unprecedented correlation with clinical outcomes (published article doi: 10.1016/j.leukres.2018.11.006)
- Patient selection and stratification: access to sample patients with complete clinical information
- High quality sample supply and logistics with a well-established network of collaborating hospitals across Europe
- Sample collection is performed in accordance with GCP guidelines and after Patient Declaration of Consent